Study of newer antibodies for B-cell lymphoma in Italy
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study watches how newer monoclonal antibodies (targeted therapies) work for people with B-cell non-Hodgkin lymphoma in real-world Italian clinics. It helps doctors learn more about how these treatments affect patients in everyday care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of lymphoma called B-cell non-Hodgkin lymphoma.
- Your doctor has decided you need treatment for your lymphoma.
- Your treatment plan includes a newer monoclonal antibody (a targeted therapy) that has been approved in Europe since 2020.
- You are not taking part in another experimental treatment trial.
- You are 18 years or older.
- You can give your permission to be in the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects blood and tissue samples from people with B-cell non-Hodgkin lymphoma who are receiving new antibody treatments. The samples help researchers understand how well these treatments work and why they might help some people more than others.
This study tests an experimental drug for people with B-cell non-Hodgkin lymphoma (a type of blood cancer) that has come back or hasn't responded to standard treatments. The goal is to see if the drug is safe and can shrink the cancer.
This study is for adults newly diagnosed with lymphoma in the last 3 months, including those who may have started treatment. It aims to collect information on patients in Italy.
This is a study that looks back and forward at people diagnosed with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or a related early condition called MBL. It aims to improve how these conditions are recognized and managed over time in Italy.
This trial tests a new mRNA treatment that helps your immune cells target and attack lymphoma cells. It's for people whose B-cell non-Hodgkin lymphoma has come back or not responded to prior treatments.
This trial tests glofitamab alone or with chemotherapy and immunotherapy in children and young adults whose “mature B-cell” non-Hodgkin lymphoma has come back or hasn’t responded to treatment. It looks at whether the study medicines can shrink lymphoma again and are safe enough to use in this age group.
Hear when a new Non-Hodgkin Lymphoma, B-cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.